Drug Research
COVID-19 Genomics UK Consortium gets £12.2 million funding to expand whole genome sequencing of SARS-CoV-2 virus
The public will be better protected from COVID-19 with £12.2 million of funding awarded to potentially life-saving research into how the virus spreads and evolves through genome sequencing.
The COVID-19 Genomics UK (COG-UK) Consortium will use the funding to expand...
Drug Research
FUJIFILM Cellular Dynamics and Lonza agree to expand the availability and use of induced pluripotent stem cell technology
FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Lonza Walkersville, Inc. (Lonza, a leading global GMP iPSC manufacturer), have entered into a worldwide agreement. The agreement enables drug...
Drug Research
Pioneering research potentially reveals early detection of prostate cancer
Pioneering research conducted by University of Virginia in collaboration with Manchester UK based APIS Assay Technologies Ltd has discovered Hormone-Upregulated lncRNA within the lymphocyte-specific protein tyrosine kinase (HULLK) is detectable in non-invasive prostate cancer patient samples.
The breakthrough data provides...
Drug Research
Ypsomed collaborates with SCHOTT and Lonza to develop a comprehensive solution for combination products based on patch injectors
Ypsomed advances its patch injector into a comprehensive solution by entering into a collaboration with SCHOTT, one of the leading suppliers of pharmaceutical primary packaging, and Lonza, a leading global partner of the pharmaceutical and biotechnology industry for the...
Drug Research
Stelis starts next phase of investment into its biologics manufacturing facility
Contract development and manufacturing organization (CDMO), Stelis BioSource, a division of Stelis Biopharma, has started the next phase of its continued investment program after having already invested more than $100 million into its facilities in Bangalore, India.
The latest phase...
Drug Research
Transcenta and Merck Announce a Strategic Collaboration at CIIE to Advance Continuous Biomanufacturing
Transcenta, a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, and Merck, a leading science and technology company, have announced a strategic technology collaboration to implement continuous manufacturing for protein therapeutics at CIIE.
“To...
Drug Research
Oxford Biomedica and PhoreMost enter gene therapy discovery collaboration
Oxford Biomedica plc , a leading gene and cell therapy group and PhoreMost Limited, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, announced that they have entered into a discovery collaboration to develop next-generation CAR-T...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read